EVC
NYMX

Eidelman Virant Capital’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Eidelman Virant Capital’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-26,796
Closed -$117K – 195
2014
Q3 		$117K Hold
26,796
– – 0.06% 161
2014
Q2 		$133K Hold
26,796
– – 0.06% 167
2014
Q1 		$146K Sell
26,796
-1,000
-4% -$5.8K 0.07% 159
2013
Q4 		$169K Buy
27,796
+8,852
+47% +$60.3K 0.07% 173
2013
Q3 		$125K Buy
+18,944
New +$124K 0.06% 134

Other funds holding NYMX

AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
WP
WMS Partners Towson, Maryland $1.78B AUM 11.82% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
MCM
Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BAS
Brown Advisory Securities Baltimore, Maryland $27.3M AUM 10.67% 1-Year Est. Return
GG
Gofen & Glossberg Chicago, Illinois $3.89B AUM 11.97% 1-Year Est. Return

Eidelman Virant Capital's NYMX Position: Q4 2014 in Review

Eidelman Virant Capital sold out of Nymox Pharmaceutical Corp (NYMX) in Q4 2014, closing a stake of 26,796 shares — an estimated $117K sold.

Eidelman Virant Capital first reported a position in NYMX in Q3 2013 and held it in 5 quarters. The position peaked at $169K in Q4 2013. 25 funds tracked by Wall St. Rank hold NYMX as of Q4 2014.

  • Eidelman Virant Capital reported no remaining Nymox Pharmaceutical Corp position as of Q4 2014 after selling out during the quarter.
  • Eidelman Virant Capital sold 26,796 Nymox Pharmaceutical Corp shares in Q4 2014, an estimated $117K.
  • Eidelman Virant Capital first reported a position in Nymox Pharmaceutical Corp in Q3 2013 and held it in 5 quarters.
  • Eidelman Virant Capital's Nymox Pharmaceutical Corp position peaked at $169K in Q4 2013.
  • 25 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q4 2014.

Based on Eidelman Virant Capital's 13F filing for Q4 2014, filed 23 Jan 2015.